Sharemaestro Newsreel

Pyxis Oncology (PYXS) CEO receives 250,956-share performance-based option grant

Pyxis Oncology's Interim CEO, Thomas Civik, has been granted a performance-based stock option for 250,956 shares, which vested on August 12, 2026. The option has an exercise price of $1.49 per share and an expiration date of February 3, 2036. This vesting occurred after …

Belite Bio (BLTE) Could Be 21% Undervalued On FDA Priority Review News

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Belite Bio (BLTE) is back in focus after the FDA accepted its New Drug Application for tinlarebant with Priority Review, a key regulatory step that …

Carlsmed (CARL) plans up to $250M in stock, debt and warrant sales

Carlsmed Inc. (CARL) has filed a shelf registration to offer up to $250 million in common stock, preferred stock, debt securities, warrants, and units. This filing allows the medical technology company to access capital markets for future funding, with specific terms for each issuance …

Northland Securities Maintains Nephros(NEPH.US) With Hold Rating, Raises Target Price to $4.75

Northland Securities has reiterated its Hold rating on Nephros (NEPH.US) but raised the price target to $4.75. This adjustment indicates a slightly more optimistic outlook on the company's future stock performance by the firm.

Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026, Deadline in Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLP

Kessler Topaz Meltzer & Check, LLP announces a securities fraud class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR). Investors who purchased CAPR securities between December 17, 2025, and July 26, 2026, have until September 28, 2026, to seek lead plaintiff status. The lawsuit …

Is Centene (CNC) Fairly Valued After Raised Outlook And Its Debt Redemption Plan?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Recent commentary on Centene (CNC) has focused on a fresh debt redemption plan and higher expectations for revenue and earnings, which together are shaping how …

Intuitive Surgical Inc. stock underperforms Friday when compared to competitors

Intuitive Surgical Inc. (ISRG) shares fell 1.68% to $394.51 on Friday, underperforming the broader market as the S&P 500 and Dow Jones also experienced slight declines. The company's stock closed 34.67% below its 52-week high, which was set on January 7th. This report highlights …

Vivos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Actuate Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Precipio, Inc. (PRPO) grows Q2 2026 revenue 24% amid going concern warning

Edgewise Therapeutics (EWTX): Baker Bros. discloses 3.4% ownership in Schedule 13G/A

Valneva (NASDAQ:VALN) Issues Earnings Results, Misses Expectations By $0.17 EPS

The Technical Signals Behind (CERT) That Institutions Follow

This article from Stock Traders Daily analyzes Certara Inc. (NASDAQ: CERT) using AI models to provide technical signals for institutional trading strategies. It highlights mixed sentiment, suggesting choppy conditions, and outlines position, momentum, and risk hedging strategies with specific entry, target, and stop-loss levels. …

Medline Inc. Class A Common Stock (NASDAQ: MDLN) Stock Price, News & Analysis

Palatin Technologies, Inc. Common Stock (NASDAQ: PTN) Share Price, PTN Stock News, PTN Share Price & Updates

Why (ASMB) Price Action Is Critical for Tactical Trading

This article analyzes the price action of Assembly Biosciences Inc. (ASMB), highlighting a mid-channel oscillation pattern and a strong risk-reward short setup. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis to …

Rubric Capital discloses 9.83% MeiraGTx (MGTX) position totaling 9.1M shares

Rubric Capital Management LP and David Rosen have reported a beneficial ownership of 9.83% in MeiraGTx Holdings plc, amounting to 9,100,000 Ordinary Shares. This disclosure was made in an amended Schedule 13G filing, indicating shared voting and dispositive power over these shares, which are …

Bio-Techne Corp (TECH) Stock News Today

Rubric Capital discloses 5.83% MannKind Corporation (MNKD) stake

Rubric Capital Management LP and David Rosen have reported a passive ownership stake of 5.83% in MannKind Corporation (MNKD), holding 18,000,000 shares with shared voting and dispositive power. This percentage is based on 308,950,166 shares outstanding as of April 24, 2026. Rubric Capital Master …

Prestige Consumer Healthcare's Jeffrey Zerillo to Retire as SVP, Operations

Prestige Consumer Healthcare announced that Jeffrey Zerillo, their Senior Vice President of Operations, will be retiring effective August 14, 2026. This information is based on an SEC filing (8-K) by Prestige Consumer Healthcare Inc. (PBH).

New owner secures mystery tenant for Everett plant shelved by Pfizer

A California developer has purchased the unfinished $350 million biomanufacturing facility in Everett that Pfizer halted after acquiring Seagen in 2023. The new owner has also secured a tenant for the plant, though the tenant's identity remains undisclosed. This development provides a future for …

Four Oculis directors' restricted stock units vest in Aug. 13 notifications

Oculis (NASDAQ: OCS) announced that restricted stock units (RSUs) granted to directors Anthony Rosenberg, Christina Ackermann, Arshad Khanani, and Robert Warner vested on August 13, 2026. The company published notifications regarding these vesting and settlement transactions. While the announcement confirms the RSU vests for …

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Oculis Holding AG has published notifications regarding transactions by persons discharging managerial responsibilities. These notifications relate to the vesting and settlement of Restricted Stock Units (RSUs) previously granted to company directors. The listed individuals include Anthony Rosenberg, Christina Ackermann, Arshad Khanani, and Robert Warner, …

Lantern Pharma Reports 46.2% Wider Q2 2026 Loss at -$0.57/Share

Vestal Point Capital (PASG) filing shows no current Passage Bio share ownership

Vestal Point Capital, LP and Ryan Wilder have filed an amended Schedule 13G/A for Passage Bio, Inc. (PASG), indicating they no longer hold any beneficial ownership in the company. The filing shows 0 shares beneficially owned and 0% of outstanding common stock, with no …

Vertex Pharmaceuticals (VRTX) Could Be 8% Undervalued Following Raised 2026 Guidance

Vertex Pharmaceuticals (VRTX) is considered 7.6% undervalued at $558.68 per share, despite its current P/E ratio of 29.7x being higher than the US Biotechs industry average. The company recently raised its full-year 2026 revenue guidance to US$13.1b to US$13.2b and completed a US$1.42b share …

HeartFlow Shares Soar Following Strong Q2 Results and Upgraded Guidance

Durable Capital discloses 6.16M Option Care shares in 13G/A filing (OPCH)

Durable Capital Partners has filed an amended ownership report for Option Care Health, Inc. common stock, revealing a 3.9% stake. Durable Capital Master Fund LP directly holds 6,163,722 shares, with Durable Capital Partners acting as the investment adviser having sole voting and dispositive power …

SYK Stock Gains 3.8% Since March-End: What's Driving the Uptrend?

Stryker (SYK) stock has seen a 3.8% gain since the end of March, outperforming its industry, driven by resilient demand, improved production, and a diversified portfolio. The company's second-quarter results showed strong organic sales and EPS growth, with key factors including the expansion of …

DOCS|Doximity Inc|Price:25.030|Chg%:-1.560

ARCH venture funds disclose 15%+ Sana Biotechnology (SANA) ownership in updated filing

ARCH venture funds and related entities, along with several individual managers, have reported an updated collective beneficial ownership of 15.3% in Sana Biotechnology (SANA) common stock as of June 30, 2026. This amounts to 45,860,681 shares based on 299,360,637 shares outstanding. Robert Nelsen, a …

Corbus Pharmaceuticals (CRBP): Citadel entities and Kenneth Griffin disclose 1.1% stake

Citadel-affiliated entities, including Kenneth Griffin, have disclosed a beneficial ownership of 206,354 shares in Corbus Pharmaceuticals Holdings, Inc. This represents a 1.1% stake in the company, based on 18,527,795 shares outstanding as of May 8, 2026. The filing indicates shared voting and dispositive power …

Vericel (VCEL) director exercises 7,000 options and sells 7,000 shares

Vericel Corp director Kevin F. McLaughlin exercised 7,000 stock options at $13.05 per share and subsequently sold 7,000 common shares at $44.53 per share on August 12, 2026. These transactions were executed under a Rule 10b5-1 trading plan adopted in May 2025. The options …

Trading Systems Reacting to (STOK) Volatility

The article analyzes Stoke Therapeutics Inc. (NASDAQ: STOK), noting a near-term neutral sentiment amidst mid and long-term strength, with an exceptional 61.2:1 risk-reward setup. It details three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored for different risk profiles and provides multi-timeframe …

PMV Pharmaceuticals Releases Q2 2026 Financial Results

PMV Pharmaceuticals reported a narrower loss for Q2 2026, with a loss of $0.34 per share compared to $0.41 in the prior year, marking a 17.1% improvement. The precision oncology company recorded a net loss of $18.1 million as it continues to invest in …

Cullinan Therapeutics, Inc. - Common Stock (CGEM) Stock Price, News, Quote & History

This article provides comprehensive information on Cullinan Therapeutics, Inc. (CGEM), including its current stock price, financial metrics, and a history of recent news and press releases. The company, a biopharmaceutical firm, focuses on developing cancer therapies and has announced several key clinical milestones and …